Clinical trial
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
NCT00308178 · Harold J. Burstein, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00308178 |
|---|---|
| Title | Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer |
| Official title | Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study |
| Lead sponsor | Harold J. Burstein, MD, PhD, Other |
| Collaborators | Celgene Corporation Industry Beth Israel Deaconess Medical Center Massachusetts General Hospital |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Abraxane |
| Enrollment | 66 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Mar 29, 2006 |
| Last update posted | Feb 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: